Depression is often coincident with chronic tinnitus , and several studies have suggested that antidepressant medications may playa role in relieving tinnitus as well as depression. We conducted a retrosp ective study ofthe use of selective serotonin reuptake inhibitors (SSRIs) by patients at a large tinnitus clinic to assess the effects of these antidepressants on tinnitus severity. We focused on a subgroup of30 patients with depression who had begun taking SSRI medication after the onset of their tinnitus ; these patients had also been treated with psychotherapy by a mental health clinician. At a mean follow-up of20.6 months, only IO ofthe 30 patients reported that they were still experiencing major depre ssion. Moreover, this group as a whole demonstrated a statistically significant improvement in tinnitus symptoms as reflected by a reduction in their Tinnitus Severity Index scores. We conclude that SSRIs represent one category oftools that can be used to help patients with severe tinnitus and depression. Like all antidepressant medications, SSRIs should be used in conjunction with psychotherapy to fa cilitate patient improvement.
Introduction
Because depression is often coincident with chronic tinnitus. ' ? several studies have investigated the effectiveness of antidepressant medications in patients with tinnitus. Some success was reported with the tricyclic antidepressants amitriptyline" and nortriptyline.v' but Mihail et al?found that trimipramine was not superior to placebo. In a 1999 review oftinnitus treatments, Dobie suggested that future studies should explore the use of the newer ant ide-pressant drugs, such as the selective serotonin reuptake inhibitors (SSRIs). 8 SSRIs increase the availability of serotonin in the brain, which often leads to the desired effects of improving patients' mood and reducing anxiety and obsessive-compulsive tendencies. This class of medications includes citalopram, escitalopram, fluoxetine, fluvoxamine, paroxetine, sertraline, and venlafaxine.
There have been few published reports of clinicians using SSRIs to treat tinnitus patients. Shemen claimed that "a trial with low-dose fluoxetine (10 mg every day) completely abolished the tinnitus in all three patients within one week."? He went on to write, "Perhaps a double-blind study with fluoxetine should be undertaken in a center with a large number of patients with this symptom, given the encouraging result of this anecdotal report."
Christensen reported the case ofa woman who switched antidepressant medications from imipramine to paroxetine. 10 "Within 8 weeks, this individual had a significant improvement in her mood disorder and a pronounced diminishment of panic attacks," he wrote. "Moreover, her tinnitus completely resol ved after the 8 weeks of treatment of paroxetine at the maintenance dose of 30 mg [per] day. "
Although reports of chronic tinnitus completely resolving after treatment with various medications are encouraging, such occurrences are rare . Consider two facts :
• Millions of people worldwide experience chronic tinnitus. • Millions of people worldwide take SSRI medication daily.
Given these facts (and the relatively high prevalence of depression among tinnitu s sufferers), it is logical to assume that thousands of tinnitus patients have taken SSRI medication. Yet few of these patients have reported that taking an SSRI stopped their perception of tinnitus. It is therefore unlikely that current SSRI medications repre- 3 4 5 overall enjoyment of life?
10. Does your tinnitus interfere with sleep? No 1 Yes, sometim es 2 Yes,often 3 11. How much of an effort is it for you to ignore tinnitus when it is present? Can easily ignore it 1 Can ignore it with some effort 2 It takes con sid erable effort 3 Can never ignore it 4 12. How much discomfort do you usually experience when your tinnitus is present? No discomfort 1 Mild discomfort 2 Moderate discomfort 3 A great deal of discomfort 4
On the scale below , please circle the number that best describes the loudness of your usual tinnitus. In this article, we describe a retrospective study that we undertook for two reasons: (1) to obtain information on a large clinic population of tinnitus patients who took SSRIs and (2) to assess the effects of SSRIs on tinnitus severity.
Patients and methods
We reviewed the records of957 consecutive patients who had been evaluated and treated in the Tinnitus Clinic at Oregon Health and Science University (OHSU) between 1996 and 2002. Detailed questionnaires had been mailed to all patients prior to their initial appointment. These questionnaires solicited information about each patient's medical, hearing, and tinnitus history. I I Included were 12 questions that constitute the Tinnitus Severity Index , which is an efficient indicator of the negative impact that tinnitus has on patients (appendix). " Patients rated the loudness oftheir usual tinnitus on a scale of 1 (very quiet) to 10 (very loud). Patients were also asked if they had ever experienced depression or were currently experiencing depression. Information from these questionnaires was entered into a database known as the Oregon Tinnitus Data Registry. 13 The initial Tinnitus Clinic visit had been conducted according to the following format:
• Members of the Tinnitus Management Team-an otolaryngologist, a neurophysiologist, and an audiologist-reviewed each patient's questionnaire and medical records prior to each patient encounter.
• Patients met with all management team members for an in-depth interview and review of their medical, hearing, tinnitus, and psychosocial histories and conditions. Patient s were educated as to the possible causes of their tinnitus, and they received reassurance and counseling regarding factors that could exacerbate or improve their condition.
• Patients underwent otolaryngologic and neurologic examinations.
• Patients underwent audiologic evaluations, including tympanometry and measurements of pure-tone air and bone conduction thresholds , speech perception in quiet and noise, and most comfortable and uncomfortable loudness levels.
• Patients underwent tinnitus evaluations, which included matching their tinnitus to sound s played through headphones, a determination of minimum masking levels, and measurements of residual inhibition (see Johnson II for a description of these procedures).
• Based on each patient's audiologic evaluation, the 110 audiologist described and demonstrated various devices to evaluate the effectiveness of acoustic therapies. These devices included hearing aids, in-the-ear sound generators, tinnitus instruments (combinations of hearing aids and sound generators), table-top sound generation machines, sound pillows, cassette tapes, and compact disks that emitted sounds of water or other masking sounds .
• The Tinnitus Management Team reviewed the results of these evaluations and explained them to each patient.
• The team then formulated its recommendations and explained them to each patient. The team also provided referral and contact information regarding physical or psychiatric evaluations, psychologic counseling, and other recommended services and products.
• Patients were encouraged to contact the clinic any time they had questions and to inform the team of their progress. Patients were contacted by telephone 1 and 3 months after their initial visit.
We mailed follow-up questionnaires to 37 patients who had started taking an SSRI following the onset of their tinnitus. We then analyzed the responses and tabulated data relating to patient demographics and their self-ratings of tinnitus loudness and severity . Mean values were calculated and compared using analyses of variance and paired t tests (two-tailed p values).
These protocols were reviewed and approved by the Institutional Review Board at OHSU . Informed consent was obtained in writing from all patients prior to their participation in this study.
Results
Of the 957 patients in our original sample, 323 (33.8 %)-204 men and 119 women (mean age: 50.6 ± 12.7 yr)reported a history of depression. A total of 253 patients (26.4%)-160 men and 93 women-reported that they had experienced depression at the time of their initial visit to the Tinnitus Clinic .
Of the 957 patients, 105 (11.0%) had alread y been taking an SSRI at the time of their initial appointment (table 1). Some 37 of these patients had started taking an SSR I after the onset of their tinnitus and prior to their initial clinic visit. All 37 patients had been diagnosed with major depression and all had received psychotherapy in addition to an SSRI. Of the 37 patients who had starte d tak ing an SSRI afte r the onset of tinnitu s, 30-18 men and 12 women, aged 26 to 73 years (mean : 52 . All 30 patients report ed that they had experienced depression at the time of their initial Tinnitu s Clinic visit. At the time of the follow-up questionnaire, only 10 of these patients repor ted that they were experienci ng depression. We calc ulated the means and standard deviations of their 11 2 self-rated tinnit us loudness according to both their initial and follow-up questionn aire responses (table 2). We found that no significa nt difference in self-rated tinnitus loudn ess had occ urred between the time of the two question naires.
We also calculated the means and standard dev iations of the 30 patie nts' responses to the 12 Tinnitus Severity Index questions and found that a significant improvement was reflected in the responses to nine of the 12 questio ns; a significant difference (p<0.005) was also reflec ted in the group's tota l Tinnitus Severity Index score (table 2) . Overall, 23 of the 30 patients had a lower Tinnitus Severity Index score on follow-up, 4 had a higher score, and 3 showed no change. (bronk Idiopathjc Urtjg ria Act.'er:.e events reportedbypat ients 12yearsofageandolder in placebo-controlled chronicidiopathicurticaria studies were similar 10 those reportedin placebo-controlled seasonalallergic rhinitisstudies.In placebo-controlled chronicidiopat hicurticariaclini caltrials.which included 726patients 12years of age andolderreceivi ng fex cfenadine hydr ochl oride tablets at doses 0120 to 240 mgtwicedaily. adverse events ere simil ar infexofenadine hydrochlorideand placebo-t reatedpatient s. Table 3listsadverseexpe riencesin patients aged12year\andolder hich werereported bygreater than2%0 1patientstreatedwithfexofenadine hydrochloride 60mgtabletstwicedailyincontroll edclinicalstudiesin the UnitedSta tes and Canada and that wer e more common with fexo fenadine hydrochloride than pl acebo. The safety of fexctenadine hydrochloridein the treatmentofchronicidiopa thicurticaria inpediatricpatients6 10 11year\ 01age is basedon thesafety profil e 01fexofenadinehydrochloride inadults and adolescent patients at dosesequal toor higher thanthe recommendeddose(seePediatric Use). OVl RDOSAGE Reports offexclenadinehydrochloride overdose have beeninfrequent andcontain limitedinformation. However. dizziness.drowsiness, and drymouth have beenreport ed.Single doses01Iexolenadine hydrochl oride upto800mg{sixnormalvolunteers at thisdoseleooeQ , anddoses upto 690mgtwice dail yfor1 mont h{three normal vchmteersat this doseleveQor 240mgoncedailyfor 1 year{234normalvolunteersat this doseleooeQwere admi nistered.....ithoul the developmentofclinicall ysignificant adverse events ascomparedto placebo. In the eooent 01O\'erdose, consider slandard meawres to remove any unabsorbeddrug.Sy mptomaticand supportivetreatment is recommended. Hemodialysis didnot effectively remove fexolenadine hydroc hloridefromblood(1.7% remO\'ed)foll owingterlenadine admi ni.. tration. Nodeaths occurredat oraldosesof lexofenadine hydr ochl oride up10 SOOO mgtkg inmice(110 limesthemaximum recommendeddailyoral doseinadultsand200times themaximu mrecommendeddailyoraldoseinchildrenbasedonmglm'andupto 5000mflkg in rats{23O times themax imum recommendeddaily oraldoseinadultsand400l i m~themaxim umrecommended dailyoraldoseinchildren basedonmgl m' . Additionally, noclinical signsol loxi ci tyorgross pathologicalfindingswereobsel'\'td. Indogs. noevi denceoftoxicity ..... asobserved atoraldoses up102000mflkg(300 limesthemax imum recommendeddailyoraldoseinadultsand530timesIhemaximum recommendeddai lyoraldose in childrenbased on mglni). 
I'IaIWl<l
TeratogenicEff tcts: Category(. There wasnoC' fiden ce ofteratogenicityinrats or rabbitsat oraldoses ol terlenadi neupto 300my'kg (.....hich ledto fexofenadine exposu resthat were approxi mately4 and 31times. r~pect i v e l y , the exposurefromthemaximumrecommendeddailyoral doseof fexofenadine inadults). Thereare no adequate and wellcont roll edstudiesin pregnanl women. Fexolenadine mould beused during pregnancyonlyif the potential benefi t justifi esthe pot ential risktothe fet us. Nonteratogenic Eff em. Dose-relateddecreasesin pup weight gainandwrvival wereobsel'\·edin rats exposed to anoraldoseof1SO ms'kg ofterlenadine(approxi mately3timesthe maximum recommendeddai lyoraldose01fexolenadine hydrochlorideinadults based oncompar· oon of fexolenadinehydrochloride AUu ). NuningMothm Thefe arenoadequat e andy, t ll<ontroll edst ud i~in",-omen during laetal ion. Becausemanydrugsare excretedin humanmi lk.caution!JJ ould beexercised when lexofenadine h)'rlrochloride isadmini stered 10a nun.ing woman.
Therecommendeddoseinpatients6to 11)t ar\ ofageisbased oncros s-sl udycomparison ofthe pharmacokinetiGofALUGRA inadultsand pediatric palientsandonthesaf etyprofileoflexofeoadine hydrochloride in bolhadult andpediatricpatients at dosesequal10orhigherthan therecommendeddoses. Thesafety ofALlEGRA tabletsala doseof30mgtv. icedailyhas beendemon stratedin438pediatric patients6to 11year\ofagein tv. 'oplac e-bo<ontrolled 2-weekseasonal allergic rhinitistrials.The salety ofALLEGRA forthetreatmentofchronicidiopalhicurticaria inpatients6to 11 year\ofageisbased oncros s-study comparison 01theptlarmacokinetiG01Al LEGRA inadult and pediatri c patientsand onthe\alelyprofile01 lexofenadine in bothadull and pedialric patients at doses rqual to or higherthanIhe recommendeddose. The effectivenessofALLEGRA lorthetreatment ofseasonalall ergicrhinitisinpatients 6to11year\ofage wasdemonstrated inone trial (n=411) in which ALLEGRA lablets 30 mg twice daily significantlyreduced lotal symptom scores compared to placebo. along with ext rapolation of demonstratedeffi cacyin pat ients ages12year\ and above, and the pharmacokineticcomparisons inadult s andchildren. The ellecti\' enC' los of ALLEGRA for the Ireatment ofchronic idiopathic urticariainpatients6to 11)' ea~of ageisbased onan ext rapolation01thedemonstratedeffi · cacy ofALLEGRA inadults",iththiscondition and the [ikelihoodthat thediseasecourse, pathophysiology and Ihe drug's ellect ares u~ta n t i a l · Iysimilar in childrento that ofadult pat ient s. Three clini calsafety studiescomparing15 mg 810 (n=8S)and 30mgBID (n=330)of anexperimental lormulalionol lexofenadine to pl acebo (n=430)have beenconductedin pediatricpatientsaged6months to 5year5. Ingeneral.fexofena dinehydr ochloridewas.....elltoleratedinthese studies. Nounexpect edadverseevents.....eresetn given Ihe knOYo'nsafely profile offexolenadine and like lyadyerse reactions forthis pati ent popul ation. (SeeADVERSE REAGlONS andClI NICAL PHARMA COLOGY.) Thesaletyandellectivenessoffexo fenadine hydrochloride in pediatric palient s under6year\ ofage ha\·e nol beenestablMed.
li<lHlri<..!il<
Oinical studies01ALLEGRA tabl etsand capsules did notinclude sufficien l numbers of wbjectsaged65 year\ and O\t r 10 determine Vl'hfther Ihispopulation responds dillerently from younger patients. Other rt ported clinicalexperiencehas not idenlifledd i l l er e nc~in r~po n ses betweenthegeriatric and youngerpatients.Thisdrugisknown 10besubstantiallyexc retedbythekidney,andtheriskoftoxi c reactions10this drug maybegreate r inpatient s wilhimpairedrenalfunction. 8ecalnC' elderlypat ientsare morelikely10 havedecrem renallunct ion. care shoul d betaken indoseselection,andmaybe~u lto moni torrenal function. (SeeClI NICAL PHARMACOLOG'1. AD VERSE: RUmO NS Smonal "'!mic Rhjnitis Adulb. Inplacebo<ontrolled seasonal allergic rhini tisclinic.llt rials inpat ient s 12yearsofage and older. y,hichincluded2461 patients receiv· ingfexofenadineh)'drochloride capsules at doses of20 mgto 240mgtwi ce daily , ad'o-me ('\."tnts ere similar infexofenadinehyd rochloride and placebo-treated patients. All ad\trse('\.'Cnts thaIwerereported bygreater than 1%ofpatients horecei\·edthe recommended dail ydose of fexofena dinehydrochloride (GO mgcapsules twice daily) . and thai were morecommon .....ith fexofenadine h)-drochloride thanplacebo . are list ed in Table 1 .
In a placebo<ontroll ed dinical study in Ihe United St.1t~. which incl uded 570 patientsaged 12 )'ear5 and older receiving lex olenadine hydrochloride tablets at doses 01120or180mgoncedaily. adverse ('\.'entswere simi lar in fexofenadine hydrochlorideand placebo-treated patients. Table 1alsolistsadverse expe ri e nc~thaIwere reportedbygreaterthanl% 01patients Ireatedwithfexofenadine hydrochloride tabl ets at doses 01180 mgonce dailyand that.....eremore common with fexofenadine hydrochloride lhan placebo. The incidenceofadverseevents, includingdr owsi n~s . was not dose·relatedandwassimilaracross wbgroups definedbyage,gender,andrace. References: I . Howarth PH, Stern MA , Roi L, Reynolds R, Bousquet j. Double-blind, placebo-controlled study comparing the efficacy and sofety01fexafenadine hydrochloride 11 20 and 180 10 9 once doily) and celirizine in seasonal allergic rhinitis. 
Discussion
The prevalence of both current (26.4 %) and lifetime (33.8%) depression was much greater in our study population than in the general population. Dobie and Sullivan estimated that the prevalence of current major depression in the general adult population is 5% and the lifetime prevalence of major depression (one or more bouts) is 15%-10% among males and 20% among females." Goldberg reported that the prevalence of depression is high in groups of patients afflicted with various chronic medical conditions (table 3) . 15 Because patients in our study were evaluated and treated at a specialized clinic, we can assume that most of them perceived their tinnitus to be a significant and sometimes debilitating problem. It is therefore not surprising that the prevalence ofdepression in our study population was high and similar to that observed in other groups of patients who experienced chronic medical conditions. Erlandsson et al reported that the prevalence of current depression among a population of tinnitus clinic patients in Sweden was between 25 and 30%. 16 Studies conducted by Sullivan et al,1 Folmer et aV· 3 and others demonstrated that tinnitus severity is positively correlated with the presence and severity of depression. Sullivan et al wrote, "treatment ofthe concurrent affective illness may reduce disability due to tinnitus. "! Folmer et al came to a similar conclusion: "successful treatment of depression with medication and/or psychotherapy can reduce the severity of tinnitus for many of these patients.'?
Folmer recently reported the results of a long-term follow-up study of patients who completed the OHSU greater reductions in tinnitus severity scores than did patients who continued to experience insomnia and depression at follow-up (table 4) .
Therefore, it is imperative to identify depression when it is present in patients who seek treatment for tinnitus. A question such as Do youfeel depressed? in written or oral form will identify most of these patients. However, some patients do not readily admit the presence or severity of their own depression. An instrument such as the Beck Depression Inventory " or the shorter version of this questionnaire" is useful for identifying and assessing the severity of patients' depression.
SSRIs reduce the frequency and severity of depressive episodes in many patients . However, the United States Agency for Health Care Policy and Research reported that "newer [SSRI] antidepressants have similar efficacy and total dropout rates compared to older antidepressants [such as tricyclic antidepressants]. Because of similar efficacy, both newer and older antidepressants should be considered when making treatment decisions.'?"
Christensen warned that "tinnitus can sometimes be a side-effect to tricyclic antidepressants. There have been numerous reports of tinnitus developing after the initiation of imipramine, amitriptyline, and doxepin."!" In fact, most psychotropic substances, including the SSRIs, have the potential to trigger tinnitus in a small percentage of patients." However, like tinnitus caused by large doses of aspirin, most cases of tinnitus attributable to antidepressants or anxiolytics are reversible after patients stop taking these medications. Fear of an unlikely side effect such as tinnitus should not keep patients from trying a medication that has a good chance of improving their condition. Similarly, patients who already have chronic tinnitus should not resist trying physician-recommended medications because of unfounded fears that their tinnitus might become louder. In most cases, it is difficult to predict how a particular medication will affect a patient or his or her tinnitus.
Matthew Rudorfer, MD, of the National Institute of Mental Health , has said, "It 's clear that in the effective treatment of depression, one has many options, all of which work . What can make the difference, therefore, is how well matched a given individual with depression is with a given treatment.':"
Patients with depression and chronic tinnitus have a better chance of experiencing improvement in both conditions when they are assessed and managed within a multimodal program. A statement written by Goodhill could apply to both conditions: "Any management which is based upon a single panacea for the treatment of a symptom and not a disease will result in failure.?" Other clinicians agree that a combination of tinnitus management strategies is more effective than one form of remediation used in isolation.":" 40 .79 ± 9.28 NS* by 3 or more points 112 patients whose follow -up BOI score stayed 34.42 ± 9.75 30.7 6 ± 9.89 0.0 00 2 within 2 points of their initial score * Not statistically significant.
The 30 patient s in our study who returned follow-up questionnaires experienced significant long-term improvement in tinnitu s severity and a significant reduction in the prevalence of current depression. SSRI antidepressants facilitated some of this improvement, but these medications were not the only treatment s that had been prescribed or used. All of these patients had attended a series of psychotherapy sessions conduct ed by a psycholo gist or psychiatrist. Moreover, all received counseling, education, and reass urance in a specialized tinnitus management program. Finally, these patients followed specific individualized recommendations with respect to acoustic therapy, lifestyle changes, and strategies to improve sleep patterns, increase relaxation, and decrease anxiety (see Folmer '? for more detailed descripti ons of these recommendations). The long-term improvements in sleep patterns and tinnitu s severity experienced by these 30 patients were similar to those observed in larger groups of patients who were evaluated and treated in our clinic . 17.29 Because tinnitu s that has been present for I year or longer is likely to persist indefinitely, we should help patients learn how to live with this symptom so it does not detract from their enjoyment of life. This can be a very time-consumin g process. When necessary, we refer patients to a mental health professional for evaluation and psychoth erapy. Psychoth erapy or counseling can reduce the severity of tinnitu s and depre ssion. A series of effec-116 tive counseling sessions is required to identify and begin to change counterproductive thought s and behaviors exhibited by some patients. In fact, psychotherapy should be given priority over medication in the treatment of depression, anxiety, and obsessive-compul sive disorder s. For complex problems such as these, medication alone is not sufficient.30
